High-tech disease profiling is the next stage in the fight against cancer

Press/Media: Research

Description

Emily McDaid met with Prof Richard Kennedy to discuss the Stratified Medicine Group, a partnership between Queen’s University Belfast and Almac Diagnostics.

Prof Richard Kennedy is professor of medical oncology at Queen’s University Belfast, and the medical director and global vice-president of biomarker development at Almac Diagnostics, a research group launched in 2011, having received funding from Invest NI.

Period30 Oct 2017

Media contributions

1

Media contributions

  • TitleHigh-tech disease profiling is the next stage in the fight against cancer
    Degree of recognitionInternational
    Media name/outletTechwatch
    Media typePrint
    Country/TerritoryUnited Kingdom
    Date30/10/2017
    DescriptionEmily McDaid met with Prof Richard Kennedy to discuss the Stratified Medicine Group, a partnership between Queen’s University Belfast and Almac Diagnostics.
    Producer/AuthorSilicon Republic
    URLhttps://www.siliconrepublic.com/innovation/disease-profiling-cancer-almac
    PersonsRichard Kennedy
View all 1
View less